Jennifer L. Porter

Jennifer L. Porter is a partner in the Life Sciences group at Goodwin. Jennifer has years of experience counseling clients in the life sciences industry through their most important strategic transactions and disclosure and governance issues.

Jennifer focuses primarily on the representation of public and private pharmaceutical, biotechnology, and medical device companies, advising on a broad range of complex transactions and corporate matters, including capital markets transactions, mergers and acquisitions, Securities Exchange Act reporting, corporate governance, licensing and collaboration transactions, and other strategic transactions.

Jennifer also regularly counsels boards and senior management on a broad range of governance strategic matters, including fiduciary duties, compliance issues, and organizational matters.

Prior to joining Goodwin, Jennifer practiced at another large international law firm.

Jennifer’s representation of life sciences companies spans the corporate life cycle, including formation matters, general corporate representations and counseling, public and private securities offerings, and mergers and acquisitions. Her recent matters include:

Capital Markets

• Century Therapeutics, Inc. in its $242.7 million initial public offering*
• Collegium Pharmaceutical, Inc. in its $210 million offering of senior convertible notes
• Larimar Therapeutics, Inc. in its $172.5 million underwritten public follow-on offering
• Collegium Pharmaceutical, Inc. in its $143.75 million offering of senior convertible notes*
• Sagimet Biosciences Inc. in its $112.5 million underwritten public follow-on offering
• Larimar Therapeutics, Inc. in its $80.5 million underwritten public follow-on offering*
• Ocugen, Inc. in its $100 million registered direct offering*
• Ocugen, Inc. in its $53.5 million public follow-on offering*
• Societal CDMO, Inc. in its $35.6 million concurrent public offerings of common and preferred stock*
• Recro Pharma, Inc. in its $30.0 million underwritten public follow-on offering*
• TELA Bio, Inc. in its $57 million initial public offering*
• TELA Bio, Inc. in its $55.2 million underwritten public follow-on offering*
• TELA Bio, Inc. in its $36.8 million underwritten public follow-on offering*
• Windtree Therapeutics, Inc. in its underwritten public offering and uplisting to Nasdaq*
• Zynerba Pharmaceuticals, Inc. in its $57.5 million underwritten public follow-on offering*
• Zynerba Pharmaceuticals, Inc, in its $48.3 million initial public offering*
• Represented underwriters in multiple equity offerings and at-the-market offerings for life sciences issuers*

Mergers & Acquisitions

• Globus Medical in its $3.1 billion merger with NuVasive, Inc.
• Collegium Pharmaceutical in its $604 million acquisition of BioDelivery Sciences International*
• Eli Lilly and Company in its acquisition of Disarm Therapeutics for up to $1.22 billion*
• Collegium Pharmaceutical in its $375 million acquisition of the nucynta franchise of products from Assertio*
• Zynerba Pharmaceuticals, Inc. in its $200 million sale to Harmony Biosciences
• Societal CDMO, Inc. in its $130 million sale to CoreRX, Inc.
• Chondrial Therapeutics in its reverse merger with Zafgen, Inc. to form Larimar Therapeutics, and concurrent $80 million private placement*
• Renovacor, Inc. in its sale to Rocket Pharmaceuticals, Inc.*
• Societal CDMO, Inc. in its $50 million acquisition of IRISYS, a San Diego-based CDMO*
• Recro Pharma, Inc. in its $175 million acquisition of a phase two product candidate and a manufacturing, formulation, and development business*
• Renovacor, Inc. in its merger with SPAC Chardan Healthcare Acquisitions 2 Corp. and concurrent private placement*
• ALKA bello in its acquisition of Otiprio and in other acquisitions and divestitures*

* Denotes experience prior to joining Goodwin

Before joining Goodwin, Jennifer was a partner at Troutman Pepper Hamilton Sanders LLP. She also previously practiced as a Senior Associate at Hogan Lovells LLC, as an Associate at Pepper Hamilton, and as an Associate at Dechert LLP.

She was a Legal intern for Judge Theodore McKee, United States Court of Appeals for the Third Circuit from 2006 to 2007.

The American Lawyer 2024 Dealmaker of the Year (along with Rachael Bushey)

2022 Women of Distinction, Philadelphia Business Journal

• Panelist, “Key Strategies for Navigating Your Career ,” Association of Corporate Counsel (ACC) Greater Philadelphia Chapter -Women’s Summit, November 16, 2022
• Panelist, “State of the Market: Trends and Issues in Health Care and Life Sciences Transactions,” ACC Greater Philadelphia In-House Counsel Conference, May 4, 2022
• Co-Author, “SEC’s Division of Corporation Finance Revises CD&Is on Non-GAAP Financial Measures,” Troutman Pepper, December 16, 2022
• Co-Author, “Going Public? For Life Sciences Companies, Pivoting in a Down Market,” Westlaw Today, November 17, 2022
• Co-Author, “Going Public? For Life Sciences Companies, Pivoting in a Down Market,” Reuters, November 17, 2022
• Co-Author, “Get Ready for the Biotech Market Rebound,” Reuters, July 28, 2022
• Co-Author, “What’s Next in Biotech’s Deal Playbook?,” Life Science Leader, July 1, 2022
• Co-Author, “SEC Proposes Rule Amendments for Beneficial Ownership Reporting,” Troutman Pepper, February 28, 2022
• Co-Author, “ SEC Proposes Rule Changes Shortening the Securities Settlement Cycle to T+1 By March 31, 2024,” Troutman Pepper , February 28, 2022
• Co-Author, “SEC Proposes Rule Amendments Relating to Rule 10b5-1 and Insider Trading,” Troutman Pepper, December 17,2021
• Co-Author, “SEC Proposes Rule Amendments to Improve Disclosures Relating to Share Repurchases,” Troutman Pepper, December 16, 2021
• Featured, “Women of Distinction 2022: Jennifer Porter, Troutman Pepper Hamilton Sanders,” Philadelphia Business Journal ,November 17, 2022
• Quoted, “Is a Rebound in the Offing for Biotech Investment?” Alternatives Watch, August 17, 2022
• Quoted, “One Year In, SEC’s Gensler Has Delivered a Rulemaking Storm,” Law360, April 15, 2022
• Interviewed, “Q&A With Jennifer Porter, Partner, Troutman Pepper,” Applied Clinical Trials, April 11, 2022